We then hypothesized that ALDH3B2 promotes CCA progression by upregulating ITGB1 and activating the ITGB1 downstream signaling pathway including c-Jun, ERK1/2, and p38 MAPK pathway. Here, ALDH3B2 is linked to cholangiocarcinoma.